Details for Patent: 10,213,393
✉ Email this page to a colleague
Which drugs does patent 10,213,393 protect, and when does it expire?
Patent 10,213,393 protects OSMOLEX ER and is included in one NDA.
Summary for Patent: 10,213,393
| Title: | Composition and method for treating neurological disease |
| Abstract: | The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof. |
| Inventor(s): | Meyer; Glenn A. (Wilmington, NC), Faour; Joaquina (Ciudad Autonoma de Buenos Aires, AR), Pastini; Ana Cristina (Ciudad Autonoma de Buenos Aires, AR), Befumo; Marcelo Fernando (Ciudad Autonoma de Buenos Aires, AR) |
| Assignee: | Osmotica Kereskedelmi es Szolgaltato Korlatolt Feleossegu Tarsasag (Budapest, HU) |
| Application Number: | 15/898,143 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Device; |
Drugs Protected by US Patent 10,213,393
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Supernus Pharms | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-001 | Feb 16, 2018 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT | ⤷ Sign Up | ||||
| Supernus Pharms | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-004 | Apr 22, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT | ⤷ Sign Up | ||||
| Supernus Pharms | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-002 | Feb 16, 2018 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT | ⤷ Sign Up | ||||
| Supernus Pharms | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-003 | Feb 16, 2018 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
